This respiratory syncytial virus (RSV) season is the first time vaccination for this potentially serious infectious disease ...

The safety and immunogenicity of Arexvy in adults aged 18 to 49 years at increased risk of RSV disease (n=395) was compared with adults aged 60 and older (n=417) in a phase 3b open-label trial ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a Phase 3 trial. Read more here.

Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world. It had an exceptional launch and generated £1.2 billion in sales in 2023.

AREXVY is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are ...

The FDA approved the first RSV vaccine Wednesday, called Arexvy, which is designed to be given as a single shot to adults 60 and over.

In addition, Arexvy is approved for prevention of LRTD caused by RSV in adults ages 50 to 59 years who are at increased risk for the disease; this group includes those with chronic diseases such ...

All three RSV vaccines -- GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA -- are FDA-approved for all adults age 60 and up (and one RSV vaccine, Pfizer's Abrysvo, is FDA- approved and CDC ...

Older adults who took the respiratory syncytial virus (RSV) vaccine Arexvy at the same time as the adjuvanted seasonal quadrivalent flu shot had an adequate immune response and tolerated it safely ...